Vabysmo 28.8mg (IVT) Faricimab
Intended for healthcare professionals only
This material should not be used as a substitute for professional medical advice or to promote any medication. For more information, please consult your physician
VABYSMO is the first and only FDA-approved treatment designed to block 2 causes of vision loss (VEGF and Ang-2†)
VABYSMO (faricimab-svoa) is a vascular endothelial growth factor (VEGF) inhibitor and angiopoietin-2 (Ang-2) inhibitor indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), and Macular Edema following Retinal Vein Occlusion (RVO).
Full prescribing information is available on request.
If you have a scientific query related to one of Roche's products, please contact us at [email protected]
In case of any adverse events or safety queries, please contact [email protected]
†The benefit of blocking Ang-2 has not been fully determined. Ang-2=angiopoietin-2; VEGF=vascular endothelial growth factor.
M-PK-00002297
Solutions
Pharma Products
![[Product] Vabysmo](https://assets.roche.com/f/169232/1280x730/fb20d16159/vabysmo-image.jpg/m/320x180/filters:format(webp):quality(90)/)